A Study of LY3437943 in Participants Who Have Obesity or Are Overweight
NCT04881760 on ClinicalTrials.gov · last registry update 2023-09-13
An unusually large phase 2: 338 participants, more than double the 110 typical for the stage. The sponsor logged completion for 16 May 2022. Primary outcome, as filed: Mean Percent Change From Baseline in Body Weight. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 338
- Started
- 2021-05-20
- Primary completion
- 2022-05-16 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Mean Percent Change From Baseline in Body Weight
Conditions studied
Obesity · Overweight
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.